May 25, 2017 | Stanford California
Hoover IP² with Global Competition Review


8.30: Welcome coffee and registration

9.00: Chairs’ morning welcome

James Kress, Baker Botts, Washington, DC
Prof. Stephen Haber, Hoover Institution, Stanford University, Palo Alto

9.10: Keynote Address

F. Scott Kieff, George Washington University and Commissioner, US International Trade Commission, Washington, DC 

9.55: Is IP a barrier to entry or a source of innovation?

Two decades ago, there was an academic consensus that IP is a source of innovation and economic growth. More recently, some academics have questioned this view, suggesting that recent changes in technology and business methods make IP more of a barrier to entry, used to protect incumbent firms. This panel of academics will discuss the current state of the evidence and debate where and if the line can be drawn.

Prof. Stephen Haber, Hoover Institution, Stanford University, Palo Alto

Mark Lemley, William H. Neukom Professor of Law, Director, Stanford Program in Law, Science and Technology, Stanford University, Palo Alto
Jonathan Barnett, Professor of Law, USC Gould School of Law, Los Angeles
Lee Branstetter, Professor of Economics and Public Policy, Heinz College and Department of Social and Decision Sciences, Carnegie Mellon University, Pittsburgh
Kayvan Noroozi, Noroozi PC and President & CEO, Koios Pharmaceuticals, Santa Monica

11.20: Coffee break

11.50: Do licensing-intense industries present a challenge for competition authorities around the world?

Industries that produce interoperable, networked goods tend to be characterised by complex value chains, in which firms are highly specialised and earn revenues via licensing.  What are the theoretical and empirical challenges faced by competition authorities, and by firms, that operate in these licensing-intense industries?

James Kress, Baker Botts, Washington, DC

Alexander Galetovic, Universidad de los Andes, Santiago
Renata Hesse, Sullivan & Cromwell, Washington, DC
Gil Ohana, Senior Director, Antitrust and Competition, Cisco Systems, San Francisco
Kurt Kjelland, Senior Director, Legal Counsel, Qualcomm, San Diego

13.10: Networking lunch 

14.10: Chairs’ afternoon welcome

James Kress, Baker Botts, Washington, DC
Prof. Stephen Haber, Hoover Institution, Stanford University, Palo Alto

14.20: Pharmaceutical pricing and public policy

Do pharmaceutical companies exploit monopoly power to the detriment of the consumer, as some governments globally, from the new US administration to India, seem to believe? Or are strong protections necessary in order to ensure the next breakthrough? This panel will discuss the impact of public policy and current enforcement trends on the pharmaceutical sector, including:

  • Licensing issues globally
  • Reverse payment issues
  • IP merger remedies
  • Product hopping

J. Mark Gidley, White & Case, Washington, DC

Michael Perry, Baker Botts, Washington, DC
Alan White, Analysis Group, Boston
Bernard J. “Barney” Cassidy, Juno Therapeutics, Seattle
Bryan Zielinski, Vice President and Assistant General Counsel, Pfizer, San Diego

15.45: Coffee break

16.05: International convergence – or lack thereof?

This panel will chart the path for companies between international enforcement trends, examining:

  • Extraterritoriality of US policy
  • What is the EU’s position?
  • Korea and the US – what’s changed?
  • China’s role

Jamillia Ferris, Wilson Sonsini Goodrich & Rosati, Washington, DC

Ekaterina Rousseva, DG Competition, European Commission, Brussels
H. Stephen Harris, Jr., Winston & Strawn, Washington, DC, Shanghai and New York
Dina Kallay, Director, Competition & Intellectual Property, Ericsson, Washington, DC
Koren Wong-Ervin, Director, Global Antitrust Institute (GAI), Adjunct Professor of Law, Antonin Scalia Law School, George Mason University, Arlington

17.25: Chairs’ closing remarks

James Kress, Baker Botts, Washington, DC
Prof. Stephen Haber, Hoover Institution, Stanford University, Palo Alto

17.30: Close of conference